BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23504064)

  • 1. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.
    Kim D; Kang E; Hwang E; Sun Y; Hwang Y; Yom CK; Kim K; No JH; Kim YB; Kim SW
    Fam Cancer; 2013 Dec; 12(4):621-8. PubMed ID: 23504064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
    van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
    Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
    Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
    Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
    Cohen JV; Chiel L; Boghossian L; Jones M; Stopfer JE; Powers J; Rebbeck TR; Nathanson KL; Domchek SM
    Fam Cancer; 2012 Mar; 11(1):69-75. PubMed ID: 21898151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
    Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
    Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    Solsky I; Chen J; Rebbeck TR
    Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
    Rebbeck TR; Kauff ND; Domchek SM
    J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
    Wang Y; Song Z; Zhang S; Wang X; Li P
    Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.
    Meiser B; Price MA; Butow PN; Karatas J; Wilson J; Heiniger L; Baylock B; Charles M; McLachlan SA; Phillips KA
    Fam Cancer; 2013 Mar; 12(1):101-9. PubMed ID: 23203849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
    Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
    Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
    JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
    Manchanda R; Burnell M; Abdelraheim A; Johnson M; Sharma A; Benjamin E; Brunell C; Saridogan E; Gessler S; Oram D; Side L; Rosenthal AN; Jacobs I; Menon U
    BJOG; 2012 Apr; 119(5):527-36. PubMed ID: 22260402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?
    Manoukian S; Alfieri S; Bianchi E; Peissel B; Azzollini J; Borreani C
    Psychooncology; 2019 Sep; 28(9):1871-1878. PubMed ID: 31264307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
    Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
    Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
    Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
    Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
    Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    Nebgen DR; Hurteau J; Holman LL; Bradford A; Munsell MF; Soletsky BR; Sun CC; Chisholm GB; Lu KH
    Gynecol Oncol; 2018 Jul; 150(1):79-84. PubMed ID: 29735278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.